Nepafenac D5
(Synonyms: 奈帕芬胺 D5; AHR-9434-d5; AL-6515-d5) 目录号 : GC36721
An internal standard for the quantification of nepafenac
Cas No.:1246814-53-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Nepafenac-d5 is intended for use as an internal standard for the quantification of nepafenac by GC- or LC-MS. Nepafenac is a prodrug form of amfenac, a non-steroidal anti-inflammatory drug (NSAID) and an inhibitor of COX-1 and COX-2.1 Nepafenac is an inhibitor of prostaglandin (PG) synthase 1 (IC50 = 64.3 ?M) that inhibits the production of PGs in isolated rabbit iris/ciliary body.2 It also reduces protein and PGE2 accumulation in a rabbit model of acute ocular inflammation when applied topically at a concentration of 0.1% prior to paracentesis. Formulations containing nepafenac have been used in the treatment of pain and inflammation associated with cataract surgery.
1.Gamache, D.A., Graff, G., Brady, M.T., et al.Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacyInflammation24(4)357-370(2000) 2.Ke, T.L., Graff, G., Spellman, J.M., et al.Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriersInflammation24(4)371-384(2000)
| Cas No. | 1246814-53-8 | SDF | |
| 别名 | 奈帕芬胺 D5; AHR-9434-d5; AL-6515-d5 | ||
| Canonical SMILES | O=C(C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H])C2=CC=CC(CC(N)=O)=C2N | ||
| 分子式 | C15H9D5N2O2 | 分子量 | 259.31 |
| 溶解度 | DMSO: ≥ 100 mg/mL (385.64 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.8564 mL | 19.2819 mL | 38.5639 mL |
| 5 mM | 0.7713 mL | 3.8564 mL | 7.7128 mL |
| 10 mM | 0.3856 mL | 1.9282 mL | 3.8564 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet